Obstructive Lung Disease Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi which often cause excessive contraction of smooth muscles. The major types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric population, increase in pipeline products, growing government and non-government initiatives for spreading awareness are the major factors driving the growth of the global obstructive lung diseases market.

As per the Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was the highest in India, Nepal, Papua New Guinea, and Lesotho. COPD manifests itself as an occupational hazard in people working in agriculture, mining, plastics, and other industries.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5367

Governments across each country have implemented regulations for the production, standardization, and utilization of COPD devices. These devices are divided into categories –Class-I, Class-II, Class-III, and Class-IV, depending upon the level of risk associated.

However, stringent government regulatory requirement for the approval of asthma and COPD drugs, side effects associated with the drug treatment, and patent expiry of drugs restrict the market growth.

The global market of obstructive lung disease is expected to grow at a CAGR of approximately 8.5% during the forecast period 2017-2023.

Intended Audience

• Obstructive Lung Disease Drug Suppliers
• Obstructive Lung Disease Drug Manufacturers
• Obstructive Lung Disease Device Suppliers
• Obstructive Lung Disease Device Manufacturers
• Research And Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation

The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.

On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others

On the basis of product type market is segmented into inhalers, and nebulizers and others. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers

On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.

On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others

On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Key Players

The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players.

Some of key the players in the global obstructive lung disease market are GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. Inc. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer Inc. (U.S), Mylan (U.S.), Aerovance Inc. (U.S.), Alkermes Inc. (U.S.),  Almirall SA. (U.S.), Genentech Inc. (U.S.), Sepracor, Inc. (U.S.), Skyepharma plc (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/obstructive-lung-disease-market-5367

Moyamoya Disease Market Growth, Trends and Value Chain 2020-2027

 Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and seizures.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5275

According to the National Organization for Rare Diseases, in Japan, moyamoya disease is estimated to occur in 1 per 1 million people, and the condition is more prevalent in females under the age of 20. It is also reported that nearly 10% of cases of moyamoya disease in Asian countries have a genetic cause. Recently, two major mutations have been found to be associated with a specific population of moyamoya patients i.e. R179, and RNF213 mutations.

Intended Audience

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Diagnostic Laboratories
• Government Research Institute
• Academic Institutes and Universities

Key Players

Some of key the players in the global moyamoya disease market are Abbott Laboratories, Boston Scientific Corporation, Cephalon, Inc., Cordis Corporation, Eisai Co., Ltd, GE Healthcare, Genentech Inc., GlaxoSmithKline PLC., Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Siemens, Stryker,, Sunovion Pharmaceuticals, Inc., UCB Pharma Ltd., Valeant Pharmaceuticals International, Inc. and others.

It is noted that growing public awareness and technological advancements are the key factors driving the moyamoya disease market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and health conscious. Thus, increasing awareness has provided a push to the growth of the market. The new and existing marketers are also contributing to control this condition. For instance, on April 13, 2016, Silk Road Medical, Inc., received FDA approval for its next-generation ENROUTE Transcarotid Neuroprotection System (NPS). The NPS is specifically designed and indicated for transcarotid artery revascularization.

Various other factors such as increased incidence of neurological disorders, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the global moyamoya disease market.

Despite these drivers, there are some issues associated with moyamoya disease market. The challenges in research and development, cost of treatment, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.

It is estimated that the moyamoya disease market is expected to grow at a CAGR 7.0% during the forecast period of 2017-2023.

Segmentation

The global moyamoya disease market is segmented on the basis of diagnosis, treatment, and distribution channels.

On the basis of the diagnosis, the market is classified as a cerebral angiogram, magnetic resonance imaging (MRI), magnetic resonance angiogram (MRA), computed tomography (CT) scans, transcranial Doppler ultrasound, positron emission tomography (PET) scan, and electroencephalography (EEG).

On the basis of the treatment, the market is classified as surgical treatment and non-surgical treatment. The surgical treatment is further classified as pial synangiosis, indirect procedures, and direct arterial bypass. The sub-segment of indirect procedures includes EDAS (encephaloduroarteriosynangiosis), EMS (encephalomyosynangiosis), Omental transposition/transfer, and dural inversion. The non-surgical treatment is further classified as anticoagulation and antiplatelet therapy, and others. The sub-segment of anticoagulation and antiplatelet therapy include heparin, warfarin, aspirin, and others.

On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies and others.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/moyamoya-disease-market-5275

Research report covers the Thumb Arthritis Market Forecasts and Growth, 2020-2027

 The Global Thumb Arthritis Market is expected to grow at an approximate CAGR of 8.1% during the forecast period.

Thumb or carpometacarpal (CMC) joint arthritis is a common type of arthritis affecting the hands. In the patients with thumb arthritis, the cushion-like cartilage inside the CMC joint breaks down, causing the bones to rub against each other. Some of the common symptoms of the disease are inclusive of thumb joint pain, thumb base swelling, besides others. The prevalence of the thumb arthritis is increasing which is the major driver for the market growth. In 2016, according to a study published in the HAND (American Association for Hand Surgery) journal, the prevalence of the thumb CMC osteoarthritis was estimated to be around 8% to 12% in the general population. Moreover, growing geriatric and obese population along with the rising healthcare expenditure is estimated to boost the market growth during the forecast period. According to the World Health Organization in 2016, approximately more than 1.9 billion adults, were estimated to be overweight, accounting for 650 million obese people. Additionally, according to the World Health Organization, the world’s geriatric population is estimated to reach 2 billion by 2050 from 900 million in 2015. However, the high cost of the surgical therapeutics along with related complications is estimated to restrain the market growth during the forecast period. According to a study published in the Plastic and Reconstructive Surgery journal in 2016, the cost of therapeutic trapeziectomy with LRTI for a majority of the patients (89%) was estimated to be about around USD 2,576.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5238

Segmentation

The global thumb arthritis market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is segmented into osteoarthritis thumb arthritis, rheumatoid thumb arthritis, and others.

On the basis of the diagnosis, the market is segmented into physical examinations, imaging, fine needle aspiration (FNA), and others. The imaging segment is sub-segmented into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.

On the basis of the treatment, the market is segmented into thumb exercise, medication, surgery, and others. The medication segment is sub-segmented into OCT medications, prescription medications, and others. The OCT medications, by treatment, is further segmented into acetaminophen, ibuprofen, and others. The prescription medications sub-segment, by treatment, is further segmented into celecoxib, meloxicam, and others. The surgery segment is sub-segmented into trapeziectomy, osteotomy, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, retail pharmacies, and others.

Key players in global thumb arthritis market

The key players in the global thumb arthritis market are inclusive of BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/thumb-arthritis-market-5238

Research report covers the Spirometry Market Forecasts and Growth, 2020-2027

 The global spirometry market is predicted to exhibit a 10.03% CAGR from 2018 to 2023 (forecast period) to reach USD 1,106.76 million by 2023, as per the latest report by Market Research Future (MRFR). This can be attributed to the sharp rise in the cases of chronic obstructive pulmonary disorders (COPD) and asthma.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6539

Spirometry is a basic test conducted by clinicians to evaluate the status of lungs. It is vital for diagnosing asthma, COPD, and other breathing disorders. The tests are carried out with the help of spirometers. Factors such as the increasing elderly populace, constrained budgets of healthcare institutes, and technological advances of respiratory care devices can drive the market demand over the forecast period. Initiatives taken by governments to curb smoking, home utilization spirometers, and focus on monitoring respiratory diseases can further the spirometry market till 2023.

Report Overview

The report provides an accurate overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global spirometry market segmented on the basis of product, technology, application, end-user, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.

Spirometry Market Segment Overview

The global market is segmented by product, technology, application, and end-user. Various products in the market include table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. Based on technology, the market is segmented into volume measurement spirometry, peak flow meters (PFM), and flow measurement spirometry.

By application, the spirometry market is segmented into diagnostic and treatment monitoring. The former is further segmented into COPD, asthma, and interstitial pulmonary fibrosis. End-users in the market include research & academic institutes, diagnostic centers, hospitals & clinics, and home care.

The segments covered in the spirometry market report are analyzed with respect to four main regions – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA), with respective country-level market sizing. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market ladder.

Spirometry Market – Competitive Landscape

Prominent players in the spirometry market include Carefusion Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Nihon Kohden Corporation (Germany), MGC Diagnostics Corporation (U.S.), Vitalograph (U.K.), Schiller AG (Switzerland), COSMED srl (Italy), Hill-Rom Holdings, Inc. (U.S.), Midmark Corporation (U.S.), Smiths Medical Inc. (U.S.), and Koninklijke Philips N.V. (The Netherlands).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539

Global Respiratory Care Devices Market Show Steady Growth: Study 2027

 The global respiratory care devices market is expected to register a significant growth at 10.1% CAGR during the forecast period (2018–2023).

The respiratory care devices are used for treatment, assessment, diagnosis, and care of patients suffering from cardiopulmonary devices. Respiratory care devices are used in the treatment of lung diseases such as chronic bronchitis, tuberculosis, acute and chronic pulmonary diseases, asthma, and others. With the growing age, the function of lungs starts to decline and hence the respiratory system undergoes various physiological, functional and immunological changes. The market growth is due to the rising incidences of chronic pulmonary diseases, asthma, and others. These devices can be used in hospitals and in-home care settings as they have developed from stationary to portable ones.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6517

Factors such as the increasing frequency of respiratory diseases, increasing geriatric population, urbanization, and its adverse effects, and changes in the environment and lifestyle boosts the growth of the market. The growing demand for point-of-care diagnostic devices in developing regions is anticipated to provide new opportunities for players in the respiratory care devices market. The lack of awareness about respiratory problems, intense competition, and the cost associated with the device and the respiratory surgery hamper the growth of the market.

Segmentation

The global respiratory care devices market has been segmented on the basis of therapeutic devices, monitoring devices, diagnostic devices, accessories and consumables, application, and end-users.

On the basis of therapeutic devices, the market has been classified as pap devices, masks, ventilators, nebulizers, humidifiers, oxygen concentrators, inhalers, reusable resuscitators, nitric oxide delivery units, and oxygen hoods.

On the basis of monitoring devices, the market has been classified as pulse oximeters, pulse oximeter sensors, pulse oximeter equipment, capnographs, and gas analyzers.

On the basis of diagnostic devices, the market has been classified as spirometers, polysomnography (PSG) devices, peak flow meters, and other diagnostic devices.

On the basis of accessories and consumables, the market has been classified as disposable masks, disposable resuscitators, tracheostomy tubes, nasal cannulas, and other consumables and accessories.

On the basis of application, the market has been classified as chronic obstructive pulmonary disease (COPD), sleep apnea, asthma, infectious diseases, and other diseases.

On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory care, home care, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European respiratory care devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The respiratory care devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The respiratory care devices market in the Middle East and Africa has been segmented into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517

Wearable Injectors Market Growth, Trends and Value Chain 2020-2027

 The global wearable injectors market is expected to grow significantly over the forecast period. It is estimated that the global wearable injectors market is expected to register a CAGR of ~ 15.2% during the forecast period from 2018 to 2023. Wearable Injectors are medical devices designed to dispense large doses of the drug. Wearable Injectors are user-friendly, convenient and they lessen the need for multiple painful injections.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6491

Numerous factors such as growing demand of convenient methods of drug administration, rising prevalence of chronic diseases such as diabetes, technological advancements and design development in wearable injectors are expected to drive the growth of the market. For instance, in July 2016, Amgen received US Food and Drug Administration (FDA) approval for its on-body wearable injector, Repatha (evolocumab) Pushtronex system, a human monoclonal antibody injector.

Moreover, favorable healthcare investments by government and the rising demand for minimally invasive devices boosts the growth of the market. However, stringent government regulation for product approval and the growing preference for traditional methods of drug delivery may hamper the market growth during the assessment period.

Segmentation

The global wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.

The market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.

The market, by usage, has been segmented into disposable and semi-reusable.

The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.

The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.

The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the global wearable injectors market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.

Europe is expected to hold the second largest position in the global wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/wearable-injectors-market-6491

Swollen Knee Treatment Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 The global swollen knee treatment market is expected to register a significant growth during the forecast period (2018–2023).

Knee swelling or occasionally mentioned as “water on the knee” is a condition where excess fluid gets accumulated in an around the knee joint. This conditions in medical terms are referred to as “knee effusion”. The swollen knee can result due to injuries such as torn ligament, cartilage tear or broken bones. The increasing number of geriatric populations followed by the rising frequency of musculoskeletal diseases, a growing number of surgeries undertaken is projected to grow the global swollen knee treatment market. The operating procedure of knee replacement is inclusive of various steps taken to implant the artificial device and replacement of the damaged knee.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6406

The swollen knee treatment market is anticipated to grow due to several factors such as the growing rate of elderly aged diseases like obesity, arthritis, osteoporosis, diabetes and sports-related injuries. Contrary, due to existing and upcoming advance technologies such as minimally invasive surgery and improved implant supplies are making it more broadly accepted even by the younger population.

In spite of being a widely used technique for curing extremely debilitating diseases, such as rheumatoid arthritis, the global swollen knee treatment market is confronting some challenges such as financial slowdown which is avoiding the growth of the market. Other growth restraining factors of the global swollen knee treatment market are intense competition, huge surgical cost, growing awareness for some non-surgical treatment methods such as exercises, shoe inserts, walking aids, weight loss programs, and painkiller medicines.

Segmentation

The global swollen knee treatment market has been segmented on the basis of type and end-users.

On the basis of type, the market has been classified as medications, patient-controlled analgesia (PCA) pumps, nerve blocks, liposomal bupivacaine, and surgery. The medications have been segmented into opioids and corticosteroids and others. The surgery is segmented into arthrocentesis, arthroscopy and knee replacement. The knee replacement is further segmented into total knee replacement, unicompartmental knee replacement, and others.

On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory surgery centers, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European swollen knee treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The swollen knee treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The swollen knee treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

In the swollen knee treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.

The European market is expected to hold the second largest market share. The market growth in this region can be attributed to the rising frequency of diabetes patients, increasing number of surgeries, and increasing demand for advanced treatment procedures are boosting the European market.

The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.

The market in the Middle East and Africa is expected to account for the smallest share of the global swollen knee treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/swollen-knee-treatment-market-6406